2023
Kidney and heart failure events are bidirectionally associated in patients with type 2 diabetes and cardiovascular disease
Sharma A, Inzucchi S, Testani J, Ofstad A, Fitchett D, Mattheus M, Verma S, Zannad F, Wanner C, Kraus B. Kidney and heart failure events are bidirectionally associated in patients with type 2 diabetes and cardiovascular disease. ESC Heart Failure 2023, 11: 737-747. PMID: 38155446, PMCID: PMC10966270, DOI: 10.1002/ehf2.14601.Peer-Reviewed Original ResearchPlacebo-treated participantsKidney eventsType 2 diabetesHeart failureCV eventsBaseline factorsLow-density lipoprotein cholesterol levelsMajor adverse CV eventsEMPA-REG OUTCOMEPrior heart failureAdverse CV eventsHeart failure eventsGlomerular filtration rateLipoprotein cholesterol levelsCoronary artery diseaseCox regression modelHigh uric acidUse of therapiesCardiovascular eventsCV diseaseHF outcomesArtery diseaseCholesterol levelsFiltration rateSubsequent riskCardiorenal interactions in heart failure: insights from recent therapeutic advances
Damman K, Testani J. Cardiorenal interactions in heart failure: insights from recent therapeutic advances. Cardiovascular Research 2023, 120: 1372-1384. PMID: 37364186, PMCID: PMC11472538, DOI: 10.1093/cvr/cvad096.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsHeart failureRisk patientsCardiovascular diseaseNew therapiesHigh cardiovascular risk patientsOutcomes of patientsCardiovascular risk patientsChronic kidney diseaseHigh-risk patientsRecent therapeutic advancesSpecific drug classesHigh mortality rateHealth care expendituresCardiorenal continuumCardiorenal interactionsMRA therapyRenal endpointsCardiovascular eventsCardiorenal diseaseKidney diseaseTherapeutic advancesDrug classesTherapeutic approachesMortality ratePatients
2021
Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA‐REG OUTCOME trial
Pellicori P, Fitchett D, Kosiborod MN, Ofstad AP, Seman L, Zinman B, Zwiener I, Wanner C, George J, Inzucchi SE, Testani JM, Cleland JGF. Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA‐REG OUTCOME trial. European Journal Of Heart Failure 2021, 23: 1085-1093. PMID: 34031968, PMCID: PMC11497224, DOI: 10.1002/ejhf.2220.Peer-Reviewed Original ResearchConceptsUse of LDDiagnosis of HFHeart failureLoop diureticsHF diagnosisEMPA-REG OUTCOME trialType 2 diabetes mellitusSigns of congestionCardiovascular eventsCardiovascular mortalityOutcome trialsDiabetes mellitusPatient subgroupsPatientsDiagnosisHigh rateOutcomesMellitusT2DMDiureticsSymptomsMortalityBaselineTrials
2019
Age associated non-linear regulation of redox homeostasis in the anucleate platelet: Implications for CVD risk patients
Jain K, Tyagi T, Patell K, Xie Y, Kadado AJ, Lee SH, Yarovinsky T, Du J, Hwang J, Martin KA, Testani J, Ionescu CN, Hwa J. Age associated non-linear regulation of redox homeostasis in the anucleate platelet: Implications for CVD risk patients. EBioMedicine 2019, 44: 28-40. PMID: 31130473, PMCID: PMC6604369, DOI: 10.1016/j.ebiom.2019.05.022.Peer-Reviewed Original ResearchMeSH KeywordsAdaptation, PhysiologicalAge FactorsAgedAged, 80 and overAgingAnimalsAntioxidantsApoptosisBiomarkersBlood PlateletsCardiovascular DiseasesComorbidityDisease Models, AnimalFemaleHomeostasisHumansMaleMiceMiddle AgedOxidation-ReductionOxidative StressPlatelet ActivationPlatelet AdhesivenessReactive Oxygen SpeciesRisk AssessmentRisk FactorsConceptsRisk patientsMouse studiesPlatelet phenotypeMajor adverse cardiovascular eventsHigh cardiovascular risk patientsAdaptive increaseAdverse cardiovascular eventsCentral pathophysiological roleCVD risk patientsCardiovascular risk patientsAggressive antiplatelet therapyEffect of comorbidityAge group 40Young healthy subjectsAntiplatelet therapyCardiovascular eventsYear age cohortAdvanced ageCVD patientsGroup 40Healthy subjectsPathophysiological roleElderly populationCardiovascular pathologyPatients